While PD-L1 inhibitors dominate HCC immunotherapy, CTLA-4 inhibitors demonstrate robust antitumor activity, particularly in advanced HCC and other cancers, offering a promising approach for improving clinical outcomes through synergistic immune modulation. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.